Where does RGNT stock trade?

Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.

What sector and industry is RGNT in?

Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Regentis Biomaterials Ltd. go public?

Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.

What companies are similar to RGNT?

Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RGNT side-by-side with any of them on Quantisnow.

How can I track RGNT on Quantisnow?

Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.

RGNT

AMEX

Regentis Biomaterials Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2025

$1.89+0.22 (+13.51%)

News25/Ratings0

Price$1.89+0.20 (+11.83%)

01:30 PM04:15 PM

News · 26 weeks330%

2025-12-072026-05-31

Mix1490d

Insider9(64%)
SEC Filings3(21%)
Market2(14%)

Latest news

25 items

5dSEC
SEC Form FWP filed by Regentis Biomaterials Ltd.
FWP - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)
6dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
33dSEC
SEC Form F-1 filed by Regentis Biomaterials Ltd.
F-1 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
48dNEWS
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence networkStrengthens surgeon engagement and expands Regentis' European commercialization infrastructureHERZLIYA, IL / ACCESS Newswire / April 16, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced a collaboration with Humanitas Research Hospital in Milan, Italy, one of Europe's leading academic medical centers in orthopedics and sports medicine. This collaboration is currently
65dINSIDER
SEC Form 3 filed by new insider Reske Galit
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Geller Ehud
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Valentine Keith
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Alpert Susan Phd Md
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Dykan Jeff
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Cohen-Arazi Efraim
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Gordashnikov Arie
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Gon Ori
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Ben-Elazar Pini
3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
78dNEWS
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending in the U.S.HERZLIYA, IL / ACCESS Newswire / March 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use o
96dSEC
Amendment: SEC Form 20-F/A filed by Regentis Biomaterials Ltd.
20-F/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
99dSEC
SEC Form 20-F filed by Regentis Biomaterials Ltd.
20-F - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
99dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
99dNEWS
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected to be rolled out in clinics across the continent in 2026GelrinC is positioned to be the first ready-to-use, off-the-shelf product in the U.S. for knee cartilage repairHERZLIYA, IL / ACCESS Newswire / February 24, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the year ended December 31, 2025 and provided an update on corporate and clinical developments."2025 w
104dNEWS
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisitionHERZLIYA, ISRAEL / ACCESS Newswire / February 19, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as Chief Medical Officer (CMO). Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clinical operations across the United States, Europe, and Israel, with a particular focus on cartilage repair an
106dSEC
SEC Form SCHEDULE 13G filed by Regentis Biomaterials Ltd.
SCHEDULE 13G - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)
106dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
106dNEWS
Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs
With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026New clinical sites to support engagement with leading orthopedic surgeons and centers of excellence in key European markets, strengthening Regentis' positioning for commercial launch and broader clinical adoptionHERZLIYA, ISRAEL / ACCESS Newswire / February 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its European clinical site network into new countries, strengthening its infrastructure to support both ongoing clinical programs including its pivotal Phase III U.S. Food and Drug
118dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
119dNEWS
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.Ori Gon brings substantial public company, medtech, and capital markets experienceHERZLIYA, ISRAEL / ACCESS Newswire / February 4, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, pla
125dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

RGNT FAQ

5 questions

Where does RGNT stock trade?
Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.
What sector and industry is RGNT in?
Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Regentis Biomaterials Ltd. go public?
Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.
What companies are similar to RGNT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RGNT side-by-side with any of them on Quantisnow.
How can I track RGNT on Quantisnow?
Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.